Prestige Biologics Co., Ltd. (KOSDAQ: 334970)

Market Cap	356.09B
Revenue (ttm)	1.75B
Net Income (ttm)	-39.44B
Shares Out	61.50M
EPS (ttm)	-672.37
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	170,200
Open	5,590.00
Previous Close	5,540.00
Day's Range	5,590.00 - 5,910.00
52-Week Range	3,850.00 - 7,280.00
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	n/a

About Prestige Biologics

Prestige Biologics Co., Ltd. specializes in the development and production of biologic agents and biosimilars. Its product candidates include Herceptin for breast and stomach cancer; Avastin for colon, lung, and ovarian cancers; Humira for arthritis; PBP1510 for pancreatic cancer; Denosumab for bone loss, osteoporosis; Aflibercept for macular edema and metastatic colorectal cancer; Eculizumab for atypical haemolytic uremic syndrome; Ipilimumab for metastatic melanoma; and PBP1710 for solid tumors. Prestige Biologics Co., Ltd. was formerly known...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2015
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 334970

Financial Performance

In 2023, Prestige Biologics's revenue was 1.75 billion, an increase of 11115.88% compared to the previous year's 15.57 million. Losses were -39.44 billion, -20.67% less than in 2022.